Evidence map›Paper›PMID 41268063›Full record

ArticleJournal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques2025

Zaleplon nanospanlastics loaded transdermal patches: formulation, optimization, ex-vivo permeation, and in-vivo studies.

Ahmed A El-Shenawy, Reham A Abd Elkarim, Reda A Mahmoud, Abd El Hakim Ramadan, Ali H Alamri, Hamdy Abdelkader, Mohamed S Elafify, Essam A Mahmoud, Mohammed S Saddik, Mohamed S Mohamed

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ahmed A El-ShenawyDepartment of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Al-Azhar University, Assiut, Egypt.
Reham A Abd ElkarimMinistry of Health and Population, Assiut, Egypt.
Reda A MahmoudDepartment of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Al-Azhar University, Assiut, Egypt.
Abd El Hakim RamadanDepartment of Pharmaceutics, Faculty of Pharmacy, Port Said University, Port Said, Egypt.
Ali H AlamriDepartment of Pharmaceutics, College of Pharmacy, King Khalid University, Abha, Saudi Arabia.
Hamdy AbdelkaderDepartment of Pharmaceutics, College of Pharmacy, King Khalid University, Abha, Saudi Arabia.
Mohamed S ElafifyDepartment of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Menoufia University, Shebin El-Kom, Egypt.
Essam A MahmoudDepartment of Clinical Pathology, Faculty of Veterinary Medicine, Zagazig University, Zagazig, Sharkia, Egypt.
Mohammed S SaddikDepartment of Pharmaceutics and Clinical Pharmacy, Faculty of Pharmacy, Sohag University, Sohag, Egypt.
Mohamed S MohamedDepartment of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Al-Azhar University, Assiut, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Zaleplon (ZLP) is a commonly used sedative-hypnotic drug that has low oral bioavailability because of its poor water solubility and extensive hepatic metabolism. This study aimed to encapsulate ZLP into spanlastic nanovesicles to enhance its bioavailability via transdermal delivery. Using Span 60 and Tween 80, ZLP-loaded spanlastics were fabricated using thin film hydration technique according to 3

Indexed as

HexosesHypnotics and SedativesNanoparticlesAcetamidesAdministration, CutaneousAnimalsBiological AvailabilityChemistry, PharmaceuticalDrug CompoundingDrug LiberationMaleParticle SizePermeabilityPolysorbatesPyrimidinesRabbitsAcetamidesHexosesHypnotics and SedativesPolysorbatesPyrimidineszaleplonfactorial designHPMC K100Mspanlasticstransdermal deliveryZaleplon

Identifiers

PMID41268063
PMCPMC12626903

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.